Keytruda (pembrolizumab) – Patent‑expiry snapshot (U.S.‑centric)
| Patent/Protection | What it covers | Filing / Grant | Original 20‑yr term | Approx. expiry | Notes |
|-------------------|----------------|---------------|--------------------|----------------|-------|
| Core antibody composition (e.g., US 7,921,447 “Monoclonal antibody to PD‑1”) | The pembrolizumab IgG4 antibody itself | Filed 2008; granted 2011 | 20 years from filing (2008) | 2028 | The “big‑picture” drug patent. |
| Fab/CRD variants (e.g., US 8,158,000) | Different Fc/CRD engineering of pembrolizumab | Filed 2008; granted 2011 | 20 yrs | 2028 | Covers engineered antibody forms. |
| Method‑of‑treatment patents (e.g., “Use of pembrolizumab for treating melanoma”) | Specific cancer indications | Filed 2008–2012; granted 2012–2015 | 20 yrs | 2028–2030 | Usually the longest period; often the last barrier to biosimilar launch. |
| Combination therapy patents (e.g., “Pembrolizumab + chemotherapy for lung cancer”) | Pembrolizumab in combo regimens | Filed 2013–2017; granted 2015–2019 | 20 yrs | 2033–2037 | Some newer combos still have a few years left. |
| Formulation & delivery patents (e.g., “Lyophilized pembrolizumab solution”) | Specific drug formulation & delivery tech | Filed 2014; granted 2018 | 20 yrs | 2038 | Usually last the longest and may delay entry of generic‐style biosimilars. |
Bottom‑line timeline
| Year | What’s happening for Keytruda’s patents |
|------|----------------------------------------|
| 2024–2025 | Most of the core antibody patents (7,921,447; 8,158,000) are set to expire, or have already expired. |
| 2028 | Core antibody patents expire. Merck’s most critical “drug‑product” exclusivity ends. |
| 2028–2030 | The key indication‑based patents (melanoma, NSCLC, etc.) expire. This is the period when the first biosimilar candidates could begin their regulatory pathways. |
| 2030–2037 | Remaining combination‑therapy and formulation patents may still provide a tail‑end exclusivity for some indications. |
Why the dates matter
1. Core antibody expiry (2028) – Once the antibody itself is no longer protected, competitors can legally manufacture their own anti‑PD‑1 antibodies (biosimilars).
2. Indication patents (2028–2030) – Even after the core drug patent expires, a company can still block competitors from selling Keytruda for a particular cancer if the “use” patent is alive.
3. Formulation/combination patents (2030–2037) – These can keep Keytruda as the “preferred” formulation or combination in a market for a few extra years.
What to expect
- Biosimilar entry is most likely after 2028 but will be delayed until the indication patents in a given market expire (likely 2029–2030 for the main indications).
- Merck may file new patents (e.g., for novel dosing regimens, extended‑release formulations, or new combinations) that could extend exclusivity for a few more years.
- In some countries the expiration dates differ due to local filing dates and patent law, so the actual launch of competitors can vary internationally.
---
Bottom‑line for patients & prescribers
If you’re being treated with Keytruda, the drug will remain the sole marketed product for most indications until 2028–2030. After that, the market could see biosimilar competitors, potentially affecting price and access. The exact timing for a specific therapy (e.g., melanoma vs. lung cancer) depends on the expiration of the corresponding indication patents in each jurisdiction.